EFFICACY AND SAFETY OF XIAOAIPING TABLETS IN THE TREATMENT OF ELDERLY PATIENTS WITH INTERMEDIATE-RISK/HIGH-RISK MYELODYSPLASTIC SYNDROME: A PILOT TRIAL
(Abstract release date: 05/19/16)
EHA Library. Sun X. 06/09/16; 134828; PB1928
Prof. Dr. Xuemei Sun
Contributions
Contributions
Abstract
Abstract: PB1928
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) represent a group of biologically and clinically heterogeneous clonal hematopoietic neoplasms with very poor treatment efficacy and clinical outcomes and patients have been recommended enrolled in clinical trials. Traditional Chinese medicine has also made some progress in the treatment of MDS in resent years. Xiaoaiping tablet, an herbal medicine widely used as an anticancer wonder drug, is the extract of Marsdenia tenacissima (Tong-guan-teng in Chinese folk medicine),which is officially recorded in the Chinese Pharmacopoeia Marsdenia tenacissima. Since 1990s,Xiaoaiping preparations including tablet,injection and syrup which are all extractions of the plants, demonstrate anti-tumor effect on gastric, hepatic carcinoma and leukemia
Aims
To observe the efficacy and safety of Xiaoaiping tablets in the treatment of elderly patients(over 60 years-old) with intermediate-risk/high-risk myelodysplastic syndrome
Methods
Twenty-four patients were enrolled in the study. They received Xiaoaiping tablets (2.4-3.0g,oral,3 times daily) combined with supportive care therapy. The primary endpoint of efficacy was measured by the number of days between blood transfusions as well as haematolgical indicies. The changes in ECOG performance status were observed as well as adverse events
Results
Twenty-one patients of the twenty-four completed therapy. Two patients (9.5%) had a complete remission (CR) 3 patients (14.3%) had a partial response (PR), the overall response rate was 23.8%. Eleven patients had haematological improvement (HI), with the HI rate being 52.4%. Haematologic indices of hemoglobin, total neutrophil count and platelet post Xiaoaiping-treatment were significantly higher than those before treatment (P<0.05).After treatment, the average interval of transfusion of red blood cells (RBC) and platelets was extended (P<0.05). The ECOG scores post-treatment was lower than those before treatment (P<0.05). Toxicities were limited. There were no grade 3 or 4 adverse events
Conclusion
Xiaoaiping tablet was an efficacious intervention as measured by hematological indices, the number and frequency transfusions and patients performance status. It was an effective and safe agent in the treatment of elderly patients with intermediate-risk/high-risk MDS, and the tablets might be a promising therapy for this group of patients.
Session topic: E-poster
Keyword(s): Myelodysplasia, Treatment
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) represent a group of biologically and clinically heterogeneous clonal hematopoietic neoplasms with very poor treatment efficacy and clinical outcomes and patients have been recommended enrolled in clinical trials. Traditional Chinese medicine has also made some progress in the treatment of MDS in resent years. Xiaoaiping tablet, an herbal medicine widely used as an anticancer wonder drug, is the extract of Marsdenia tenacissima (Tong-guan-teng in Chinese folk medicine),which is officially recorded in the Chinese Pharmacopoeia Marsdenia tenacissima. Since 1990s,Xiaoaiping preparations including tablet,injection and syrup which are all extractions of the plants, demonstrate anti-tumor effect on gastric, hepatic carcinoma and leukemia
Aims
To observe the efficacy and safety of Xiaoaiping tablets in the treatment of elderly patients(over 60 years-old) with intermediate-risk/high-risk myelodysplastic syndrome
Methods
Twenty-four patients were enrolled in the study. They received Xiaoaiping tablets (2.4-3.0g,oral,3 times daily) combined with supportive care therapy. The primary endpoint of efficacy was measured by the number of days between blood transfusions as well as haematolgical indicies. The changes in ECOG performance status were observed as well as adverse events
Results
Twenty-one patients of the twenty-four completed therapy. Two patients (9.5%) had a complete remission (CR) 3 patients (14.3%) had a partial response (PR), the overall response rate was 23.8%. Eleven patients had haematological improvement (HI), with the HI rate being 52.4%. Haematologic indices of hemoglobin, total neutrophil count and platelet post Xiaoaiping-treatment were significantly higher than those before treatment (P<0.05).After treatment, the average interval of transfusion of red blood cells (RBC) and platelets was extended (P<0.05). The ECOG scores post-treatment was lower than those before treatment (P<0.05). Toxicities were limited. There were no grade 3 or 4 adverse events
Conclusion
Xiaoaiping tablet was an efficacious intervention as measured by hematological indices, the number and frequency transfusions and patients performance status. It was an effective and safe agent in the treatment of elderly patients with intermediate-risk/high-risk MDS, and the tablets might be a promising therapy for this group of patients.
Session topic: E-poster
Keyword(s): Myelodysplasia, Treatment
Abstract: PB1928
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) represent a group of biologically and clinically heterogeneous clonal hematopoietic neoplasms with very poor treatment efficacy and clinical outcomes and patients have been recommended enrolled in clinical trials. Traditional Chinese medicine has also made some progress in the treatment of MDS in resent years. Xiaoaiping tablet, an herbal medicine widely used as an anticancer wonder drug, is the extract of Marsdenia tenacissima (Tong-guan-teng in Chinese folk medicine),which is officially recorded in the Chinese Pharmacopoeia Marsdenia tenacissima. Since 1990s,Xiaoaiping preparations including tablet,injection and syrup which are all extractions of the plants, demonstrate anti-tumor effect on gastric, hepatic carcinoma and leukemia
Aims
To observe the efficacy and safety of Xiaoaiping tablets in the treatment of elderly patients(over 60 years-old) with intermediate-risk/high-risk myelodysplastic syndrome
Methods
Twenty-four patients were enrolled in the study. They received Xiaoaiping tablets (2.4-3.0g,oral,3 times daily) combined with supportive care therapy. The primary endpoint of efficacy was measured by the number of days between blood transfusions as well as haematolgical indicies. The changes in ECOG performance status were observed as well as adverse events
Results
Twenty-one patients of the twenty-four completed therapy. Two patients (9.5%) had a complete remission (CR) 3 patients (14.3%) had a partial response (PR), the overall response rate was 23.8%. Eleven patients had haematological improvement (HI), with the HI rate being 52.4%. Haematologic indices of hemoglobin, total neutrophil count and platelet post Xiaoaiping-treatment were significantly higher than those before treatment (P<0.05).After treatment, the average interval of transfusion of red blood cells (RBC) and platelets was extended (P<0.05). The ECOG scores post-treatment was lower than those before treatment (P<0.05). Toxicities were limited. There were no grade 3 or 4 adverse events
Conclusion
Xiaoaiping tablet was an efficacious intervention as measured by hematological indices, the number and frequency transfusions and patients performance status. It was an effective and safe agent in the treatment of elderly patients with intermediate-risk/high-risk MDS, and the tablets might be a promising therapy for this group of patients.
Session topic: E-poster
Keyword(s): Myelodysplasia, Treatment
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) represent a group of biologically and clinically heterogeneous clonal hematopoietic neoplasms with very poor treatment efficacy and clinical outcomes and patients have been recommended enrolled in clinical trials. Traditional Chinese medicine has also made some progress in the treatment of MDS in resent years. Xiaoaiping tablet, an herbal medicine widely used as an anticancer wonder drug, is the extract of Marsdenia tenacissima (Tong-guan-teng in Chinese folk medicine),which is officially recorded in the Chinese Pharmacopoeia Marsdenia tenacissima. Since 1990s,Xiaoaiping preparations including tablet,injection and syrup which are all extractions of the plants, demonstrate anti-tumor effect on gastric, hepatic carcinoma and leukemia
Aims
To observe the efficacy and safety of Xiaoaiping tablets in the treatment of elderly patients(over 60 years-old) with intermediate-risk/high-risk myelodysplastic syndrome
Methods
Twenty-four patients were enrolled in the study. They received Xiaoaiping tablets (2.4-3.0g,oral,3 times daily) combined with supportive care therapy. The primary endpoint of efficacy was measured by the number of days between blood transfusions as well as haematolgical indicies. The changes in ECOG performance status were observed as well as adverse events
Results
Twenty-one patients of the twenty-four completed therapy. Two patients (9.5%) had a complete remission (CR) 3 patients (14.3%) had a partial response (PR), the overall response rate was 23.8%. Eleven patients had haematological improvement (HI), with the HI rate being 52.4%. Haematologic indices of hemoglobin, total neutrophil count and platelet post Xiaoaiping-treatment were significantly higher than those before treatment (P<0.05).After treatment, the average interval of transfusion of red blood cells (RBC) and platelets was extended (P<0.05). The ECOG scores post-treatment was lower than those before treatment (P<0.05). Toxicities were limited. There were no grade 3 or 4 adverse events
Conclusion
Xiaoaiping tablet was an efficacious intervention as measured by hematological indices, the number and frequency transfusions and patients performance status. It was an effective and safe agent in the treatment of elderly patients with intermediate-risk/high-risk MDS, and the tablets might be a promising therapy for this group of patients.
Session topic: E-poster
Keyword(s): Myelodysplasia, Treatment
{{ help_message }}
{{filter}}